Cover Image
市場調查報告書

生技仿製藥的全球市場預測 2020年:重組的非糖基化蛋白質、重組的糖基化蛋白質、重組的肽

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders): Global Forecast to 2020

出版商 MarketsandMarkets 商品編碼 290171
出版日期 內容資訊 英文 153 Pages
訂單完成後即時交付
價格
Back to Top
生技仿製藥的全球市場預測 2020年:重組的非糖基化蛋白質、重組的糖基化蛋白質、重組的肽 Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders): Global Forecast to 2020
出版日期: 2015年07月16日 內容資訊: 英文 153 Pages
簡介

醫療費削減的壓力上升,對符合成本效益的替代品的需求擴大,慢性病患的負擔增加,及人口高齡化擴大等各種要素,對生技藥品和生技仿製藥和生物醫藥品的需求擴大有所貢獻。全球生技仿製藥市場,預計從2015年到2020年的預測期間內,以22.1%的年複合成長率擴大。

本報告提供全球生技仿製藥市場相關調查、市場促進成長要素、阻礙要素、機會、課題及主要的問題整體性檢討、產品與服務、應用、各地區的分析等,加上主要企業簡介,為您概述為以下內容。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 整體生技仿製藥市場
  • 生技仿製藥市場:各類型、地區
  • 生技仿製藥市場:各國
  • 重組的非糖基化蛋白質
  • 生命週期分析:各地區

第5章 市場概要

  • 簡介
  • 生技仿製藥市場區分
  • 市場動態

第6章 產業考察

  • 簡介
  • 波特的五力分析
  • 主要的開發中產品
  • 法規展望
  • 生技仿製藥服務業的考察

第7章 生技仿製藥市場:各產品類型

  • 簡介
  • 重組的非糖基化蛋白質
    • 胰島素
    • 基因改造人體生長荷爾蒙 (rhGH)
    • 顆粒細胞增生因子 (Filgrastim)
    • 干擾素
  • 重組的糖基化蛋白質
    • 促血紅細胞生長素 (EPO)
    • 單株抗體 (MAb)
    • 促濾泡素
  • 重組的肽
    • 升糖素
    • 抑鈣素

第8章 生技仿製藥市場:各用途

  • 簡介
  • 癌症
  • 血液疾病
  • 慢性、免疫疾病
  • 生長激素不足
  • 感染疾病
  • 其他

第9章 生技仿製藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他 (ROW)

第10章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢

第11章 企業簡介 (概要、財務、產品 & 服務、策略及發展)

  • 簡介
  • Hospira, Inc.
  • Sandoz International GMBH (Division Of Novartis International Ag)
  • Teva Pharmaceutical Industries Ltd.
  • Roche Holding Ltd.
  • Amgen, Inc.
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Celltrion, Inc.
  • Mylan, Inc.
  • Actavis, Inc.
  • Merck Kgaa

第12章 附錄

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 2160

Various factors have contributed to the rise in demand for biopharmaceutical products such as biologics and biosimilars. Some of these factors include the rising pressure to reduce healthcare expenditure, growing demand for cost-effective alternatives, growing burden of chronic diseases, and growing aging population. Biosimilars are similar versions of their corresponding patented biologic drugs, and are similar with regards to their quality, safety, and efficacy. The global biosimilars market is estimated to be worth $2.29 billion in 2015, and is poised to grow at a CAGR of 22.1% during the forecast period.

This report studies and analyzes the biosimilars market by product and application. On the basis of products, the biosimilars market is segmented into recombinant nonglycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant nonglycosylated proteins market is further segmented into insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormones; whereas, the recombinant glycosylated proteins market is further segmented into erythropoietin, monoclonal antibodies, and follitropin. The recombinant peptides market is segmented into calcitonin and glucagon. The recombinant glycosylated proteins segment is expected to witness the highest growth rate owing to the increased demand for monoclonal antibodies in the treatment of cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. On the other hand, the recombinant nonglycosylated proteins segment accounts for the largest share of the market in 2015. The insulin segment is poised to be the fastest-growing segment of the recombinant nonglycosylated proteins market, growing at a CAGR of 28.1% from 2015 to 2020. Growth in this insulin market is attributed to the rising incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of insulin.

On the basis of applications, the biosimilars market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and other applications (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure).

Geographically, Europe is expected to account for the largest share of the global biosimilars market in 2015 followed by Asia-Pacific. The large share of the European region can be attributed to the rising budgetary pressures to reduce healthcare expenditure, increasing aging population, growing demand for cost-effective alternatives, rising incidences of various diseases, and government initiatives. On the other hand, stringent regulatory environment, high manufacturing complexities and costs, and high-entry barriers are considered to hinder its market growth.

The global biosimilars market is highly competitive, with a large number of big and small market players. As of 2014, the global biosimilars market was dominated by Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel). Furthermore, new product launches and expansions are the major strategies adopted by major players to achieve growth in this market.

Reasons to Buy the Report:

From an insight perspective, this research report focused on various levels of analysis-industry analysis (industry trends and Porter's five forces model), market share analysis of top players, and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments in the biosimilars market; and high-growth regions/countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on biosimilar products offered by the top 10 players in the biosimilars market. The report analyzes the biosimilars market by product and application across geographies
  • Product Development/Innovation: Detailed insights on research and development activities and new product launches in the biosimilars market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various biosimilar products across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the biosimilars market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKET SEGMENTATION
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
      • 2.3.2.1. Key industry insights
  • 2.4. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION

4. PREMIUM INSIGHTS

  • 4.1. OVERALL BIOSIMILARS MARKET
  • 4.2. BIOSIMILARS MARKET, BY TYPE & REGION
  • 4.3. BIOSIMILARS MARKET, BY COUNTRIES
  • 4.4. RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET, BY TYPE
  • 4.5. LIFECYCLE ANALYSIS, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. BIOSIMILARS MARKET SEGMENTATION
    • 5.2.1. BY PRODUCT
    • 5.2.2. BY APPLICATION
    • 5.2.3. BY REGION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Growing pressure to curtail healthcare expenditure
      • 5.3.1.2. Increasing demand for biosimilar drugs due to their cost-effectiveness
      • 5.3.1.3. Rising incidences of diseases
      • 5.3.1.4. Rise in aging population triggers the incidences of chronic disorders
      • 5.3.1.5. Strategic collaborations lead to enhance productivity and clinical trial activities for biosimilars
      • 5.3.1.6. Increasing government support and initiatives to develop and promote biosimilars
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. High manufacturing complexities and costs
      • 5.3.2.2. Innovative strategies by biologic drug manufacturers
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Emerging markets
      • 5.3.3.2. Untapped indications
      • 5.3.3.3. Biologic products set to be off-patent will offer opportunities for biosimilars
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Stringent regulatory requirements to adversely affect investments in biosimilars
    • 5.3.5. BURNING ISSUES
      • 5.3.5.1. Product withdrawals provide significant opportunities for new entrants

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. PORTER'S FIVE FORCES ANALYSIS
    • 6.2.1. THREAT OF NEW ENTRANTS
    • 6.2.2. THREAT OF SUBSTITUTES
    • 6.2.3. INTENSITY OF RIVALRY
    • 6.2.4. BARGAINING POWER OF SUPPLIERS
    • 6.2.5. BARGAINING POWER OF BUYERS
  • 6.3. KEY PIPELINE PRODUCTS
  • 6.4. REGULATORY OUTLOOK
    • 6.4.1. NORTH AMERICA
      • 6.4.1.1. U.S.
      • 6.4.1.2. Canada
    • 6.4.2. EUROPE
    • 6.4.3. ASIA-PACIFIC
      • 6.4.3.1. China
      • 6.4.3.2. India
      • 6.4.3.3. Japan
      • 6.4.3.4. South Korea
    • 6.4.4. REST OF THE WORLD
      • 6.4.4.1. Brazil
      • 6.4.4.2. Mexico
      • 6.4.4.3. Argentina
      • 6.4.4.4. Saudi Arabia
  • 6.5. BIOSIMILARS SERVICES INDUSTRY INSIGHTS
    • 6.5.1. INTRODUCTION
    • 6.5.2. CONTRACT MANUFACTURING ORGANIZATIONS
    • 6.5.3. CONTRACT RESEARCH ORGANIZATIONS
    • 6.5.4. OTHER SERVICES (NONCLINICAL & BIOINFORMATICS)

7. BIOSIMILARS MARKET, BY TYPE OF PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. RECOMBINANT NON-GLYCOSYLATED PROTEINS
    • 7.2.1. INSULIN
    • 7.2.2. RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
    • 7.2.3. GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM)
    • 7.2.4. INTERFERONS
  • 7.3. RECOMBINANT GLYCOSYLATED PROTEINS
    • 7.3.1. ERYTHROPOIETIN (EPO)
    • 7.3.2. MONOCLONAL ANTIBODIES (MABS)
    • 7.3.3. FOLLITROPIN
  • 7.4. RECOMBINANT PEPTIDES
    • 7.4.1. GLUCAGON
    • 7.4.2. CALCITONIN

8. BIOSIMILARS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. ONCOLOGY
  • 8.3. BLOOD DISORDERS
  • 8.4. CHRONIC AND AUTOIMMUNE DISEASES
  • 8.5. GROWTH HORMONE DEFICIENCY
  • 8.6. INFECTIOUS DISEASES
  • 8.7. OTHER APPLICATIONS

9. BIOSIMILARS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. U.S.
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. U.K.
    • 9.3.2. GERMANY
    • 9.3.3. FRANCE
    • 9.3.4. SPAIN
    • 9.3.5. ITALY
    • 9.3.6. REST OF EUROPE
  • 9.4. ASIA-PACIFIC
    • 9.4.1. CHINA
    • 9.4.2. INDIA
    • 9.4.3. JAPAN
    • 9.4.4. SOUTH KOREA
    • 9.4.5. REST OF ASIA-PACIFIC (ROAPAC)
  • 9.5. REST OF THE WORLD (ROW)

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. COMPETITIVE SITUATION AND TRENDS
    • 10.3.1. NEW PRODUCT LAUNCHES AND REGULATORY APPROVALS
    • 10.3.2. AGREEMENTS AND COLLABORATIONS
    • 10.3.3. EXPANSIONS
    • 10.3.4. ACQUISITIONS
    • 10.3.5. OTHER DEVELOPMENTS

11. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 11.1. INTRODUCTION
  • 11.2. HOSPIRA, INC.
  • 11.3. SANDOZ INTERNATIONAL GMBH (A DIVISION OF NOVARTIS INTERNATIONAL AG)
  • 11.4. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 11.5. ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMANN-LA ROCHE LTD.)
  • 11.6. AMGEN
  • 11.7. BIOCON LTD.
  • 11.8. DR. REDDY'S LABORATORIES
  • 11.9. CELLTRION INC.
  • 11.10. MYLAN INC.
  • 11.11. MERCK KGAA

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.4. AVAILABLE CUSTOMIZATIONS
  • 12.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: BIOSIMILARS MARKET: MAJOR COLLABORATIONS (2012-2015)
  • TABLE 2: BIOLOGICS GOING OFF-PATENT TO BOOST THE MARKET GROWTH FOR BIOSIMILARS
  • TABLE 3: HIGH MANUFACTURING COMPLEXITIES AND COSTS RESTRAINING THE GROWTH FOR THE BIOSIMILARS MARKET
  • TABLE 4: LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
  • TABLE 5: GROWTH PROSPECTS IN EMERGING MARKETS FUEL THE MARKET GROWTH
  • TABLE 6: STRINGENT REGULATORY REQUIREMENTS IN MAJOR COUNTRIES IS A MAJOR CHALLENGE FOR THE BIOSIMILARS MARKET
  • TABLE 7: BIOSIMILARS IN CLINICAL TRIALS
  • TABLE 8: STATUS OF REGULATORY PATHWAY IN NORTH AMERICA REGION
  • TABLE 9: SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
  • TABLE 10: STATUS OF REGULATORY PATHWAY IN THE ASIA-PACIFIC REGION
  • TABLE 11: STATUS OF REGULATORY PATHWAY IN THE ROW
  • TABLE 12: JOINT VENTURES BETWEEN CMOS & PHARMACEUTICAL COMPANIES FOR BIOSIMILARS
  • TABLE 13: BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION)
  • TABLE 14: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 15: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 16: NORTH AMERICA: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 17: EUROPE: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 18: ASIA-PACIFIC: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 19: INSULIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 20: RECOMBINANT HUMAN GROWTH HORMONE MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 21: LIST OF APPROVED PRODUCTS FROM 2012 TO 2015.
  • TABLE 22: GRANULOCYTE COLONY-STIMULATING FACTOR MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 23: INTERFERONS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 24: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 25: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 26: NORTH AMERICA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 27: EUROPE: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 28: ASIA-PACIFIC: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 29: ERYTHROPOIETIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 30: MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 31: FOLLITROPIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 32: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 33: RECOMBINANT PEPTIDES MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 34: NORTH AMERICA: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 35: EUROPE: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 36: ASIA-PACIFIC: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 37: GLUCAGON MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 38: CALCITONIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 39: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2012-2019 ($MILLION)
  • TABLE 40: BIOSIMILARS MARKET SIZE FOR ONCOLOGY, BY REGION, 2012-2019 ($MILLION)
  • TABLE 41: BIOSIMILARS MARKET SIZE FOR BLOOD DISORDERS, BY REGION, 2012-2019 ($MILLION)
  • TABLE 42: BIOSIMILARS MARKET SIZE FOR CHRONIC AND AUTOIMMUNE DISEASES, BY REGION, 2012-2019 ($MILLION)
  • TABLE 43: BIOSIMILARS MARKET SIZE FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2012-2019 ($MILLION)
  • TABLE 44: BIOSIMILARS MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2012-2019 ($MILLION)
  • TABLE 45: BIOSIMILARS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2012-2019 ($MILLION)
  • TABLE 46: BIOSIMILARS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 47: NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 48: NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 49: NORTH AMERICA: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 50: NORTH AMERICA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 51: NORTH AMERICA: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 52: NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 53: U.S.: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 54: CANADA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 55: EUROPE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 56: EUROPE: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 57: EUROPE: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 58: EUROPE: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 59: EUROPE: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 60: U.K.: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 61: GERMANY: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 62: FRANCE: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 63: SPAIN: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 64: ITALY: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 65: ROE: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 66: ASIA-PACIFIC: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 67: ASIA-PACIFIC: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 68: ASIA-PACIFIC: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 69: ASIA-PACIFIC: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 70: ASIA-PACIFIC: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 71: CHINA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 72: INDIA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 73: JAPAN: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 74: SOUTH KOREA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 75: ROAPAC: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 76: ROW: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION)
  • TABLE 77: ROW: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 78: ROW: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 79: ROW: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 80: ROW: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 81: RECENT NEW PRODUCT LAUNCHES AND REGULATORY APPROVALS, 2012-2015
  • TABLE 82: RECENT AGREEMENTS AND COLLABORATIONS, 2012-2015
  • TABLE 83: RECENT EXPANSIONS, 2012-2015
  • TABLE 84: RECENT ACQUISITIONS 2012-2015
  • TABLE 85: RECENT OTHER DEVELOPMENTS, 2012-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL BIOSIMILARS MARKET, BY PRODUCT TYPE
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: TOP-DOWN APPROACH
  • FIGURE 4: BOTTOM-UP APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: MARKET SNAPSHOT: RECOMBINANT NONGLYCOSYLATED PROTEINS TO DOMINATE THE MARKET
  • FIGURE 8: ASIA-PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 9: EUROPE TO DOMINATE NONGLYCOSYLATED PROTEINS MARKET DURING 2015-2020
  • FIGURE 10: BIOSIMILAR MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 11: BIOSIMILARS MARKET TO GROW AT A HIGH RATE DURING THE FORECAST PERIOD
  • FIGURE 12: RECOMBINANT NONGLYCOSYLATED PROTEINS SEGMENT HELD THE LARGEST MARKET SHARE IN 2014
  • FIGURE 13: GERMANY DOMINATED THE BIOSIMILARS MARKET IN 2014
  • FIGURE 14: INSULIN SEGMENT TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020
  • FIGURE 15: ASIA-PACIFIC TO WITNESS HIGH GROWTH IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD
  • FIGURE 16: BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES
  • FIGURE 17: GLOBAL BIOSIMILARS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 18: INSULIN IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD
  • FIGURE 19: ERYTHROPOIETIN IS EXPECTED TO DOMINATE THE MARKET IN THE FORECAST PERIOD
  • FIGURE 20: GLUCAGON WILL CONTINUE TO DOMINATE THE MARKET IN THE FORECAST PERIOD
  • FIGURE 21: ONCOLOGY DOMINATES THE BIOSIMILARS APPLICATIONS MARKET
  • FIGURE 22: GEOGRAPHIC SNAPSHOT (2015): EMERGING MARKETS HOLD SIGNIFICANT GROWTH OPPORTUNITIES
  • FIGURE 23: ASIA-PACIFIC, AN ATTRACTIVE MARKET FOR BIOSIMILARS
  • FIGURE 24: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 25: RECOMBINANT PEPTIDES WILL DRIVE THE GROWTH OF THE BIOSIMILAR MARKET IN THE U.S.
  • FIGURE 26: RECOMBINANT GLYCOSYLATED PROTEINS WILL CONTINUE TO HOLD THE LARGEST SHARE IN THE EUROPEAN MARKET
  • FIGURE 27: ASIA-PACIFIC: MARKET SNAPSHOT
  • FIGURE 28: MAJOR PLAYERS ADOPTED THE STRATEGY OF APPROVALS TO ENHANCE THEIR MARKET POSITIONS IN THE BIOSIMILARS MARKET (2012-2015)
  • FIGURE 29: GLOBAL BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2014
  • FIGURE 30: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES AND REGULATORY APPROVALS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS
  • FIGURE 31: PRODUCT BENCHMARKING FOR TOP 3 PLAYERS
  • FIGURE 32: HOSPIRA, INC.: COMPANY SNAPSHOT
  • FIGURE 33: SANDOZ INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • FIGURE 34: TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • FIGURE 35: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 36: AMGEN: COMPANY SNAPSHOT
  • FIGURE 37: BIOCON LTD.: COMPANY SNAPSHOT
  • FIGURE 38: DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 39: CELLTRION INC.: COMPANY SNAPSHOT
  • FIGURE 40: MYLAN INC.: COMPANY SNAPSHOT
  • FIGURE 41: MERCK KGAA: COMPANY SNAPSHOT
Back to Top